Practical implications of gene-expression-based assays for breast oncologists

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2011.178PMID 22143140PMCID PMC3703639
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Supplemental Table 1

  2016cited by this paper
• Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

  2012cited by this paper
• TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab

  2012cited by this paper
• Prognostic utility of HOXB13 : IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial

  2011cited by this paper
• Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

  2011cited by this paper
• Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

  2011cited by this paper
• Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

  2011cited by this paper
• Microarray-Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement

  2011cited by this paper
• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

  2011cited by this paper
• The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy.

  2011cited by this paper
• Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765)

  2011cited by this paper
• Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens.

  2011cited by this paper
• Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

  2010cited by this paper
• The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.

  2010cited by this paper
• Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

  2010cited by this paper
• Clinical implementation of the intrinsic subtypes of breast cancer.

  2010cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer.

  2010cited by this paper
• The importance of platform annotation in interpreting microarray data.

  2010cited by this paper
• Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

  2010cited by this paper
• HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens

  2010cited by this paper
• Gene-expression-based prognostic assays for breast cancer

  2010cited by this paper
• Fluorescent in situ hybridization as a primary test for HER2 status in breast cancer: controversies.

  2010cited by this paper
• The importance of gene-centring microarray data.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

  2010cited by this paper
• Deconstructing the molecular portraits of breast cancer

  2010cited by this paper
• Breast cancer molecular profiling with single sample predictors: a retrospective analysis.

  2010cited by this paper
• Breast cancer prognostic classification in the molecular era: the role of histological grade

  2010cited by this paper
• Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection.

  2010cited by this paper
• Validation of a Fully Automated HER2 Staining Kit in Breast Cancer

  2010cited by this paper
• The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

  2010cited by this paper
• American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.

  2010cited by this paper
• The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study

  2009cited by this paper
• Immunohistochemical assessment of hormone receptor status of breast carcinoma: interobserver variation of the quick score.

  2009cited by this paper
• Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer – A national survey performed at pathology departments in Sweden

  2009cited by this paper
• Predicting protein-protein interactions in Arabidopsis thaliana through integration of orthology, gene ontology and co-expression

  2009cited by this paper
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

  2009cited by this paper
• Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

  2009cited by this paper
• Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis

  2009cited by this paper
• Genomic grade index is associated with response to chemotherapy in patients with breast cancer.

  2009cited by this paper
• Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy.

  2009cited by this paper
• Supervised risk predictor of breast cancer based on intrinsic subtypes.

  2009cited by this paper
• Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

  2009cited by this paper
• Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3)

  2009cited by this paper
• Histologic grading of invasive lobular carcinoma: does use of a 2-tiered nuclear grading system improve interobserver variability?

  2009cited by this paper
• Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer

  2009cited by this paper
• What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard.

  2008cited by this paper
• Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

  2008cited by this paper
• Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

  2008cited by this paper
• Direct multiplexed measurement of gene expression with color-coded probe pairs

  2008cited by this paper
• A Five-Gene Molecular Grade Index and HOXB13:IL17BR Are Complementary Prognostic Factors in Early Stage Breast Cancer

  2008cited by this paper
• Epidemiology of basal-like breast cancer

  2008cited by this paper
• Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

  2008cited by this paper
• HER-2 Gene Amplification, HER-2 and Epidermal Growth Factor Receptor mRNA and Protein Expression, and Lapatinib Efficacy in Women with Metastatic Breast Cancer

  2008cited by this paper
• Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases

  2008cited by this paper
• Development of the 21-gene assay and its application in clinical practice and clinical trials.

  2008cited by this paper
• Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

  2008cited by this paper
• Comparison of estrogen receptor results from pathology reports with results from central laboratory testing.

  2008cited by this paper
• Clinical application of the 70-gene profile: the MINDACT trial.

  2008cited by this paper
• Re: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility.

  2008cited by this paper
• Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas

  2008cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• A New Rabbit Monoclonal Antibody (4B5) for the Immunohistochemical (IHC) Determination of the HER2 Status in Breast Cancer: Comparison With CB11, Fluorescence In Situ Hybridization (FISH), and Interlaboratory Reproducibility

  2007cited by this paper
• An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer

  2007cited by this paper
• Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

  2007cited by this paper
• Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.

  2007cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays.

  2007cited by this paper
• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

  2007cited by this paper
• Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.

  2007cited by this paper
• A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer

  2007cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• Interobserver agreement and reproducibility in classification of invasive breast carcinoma: an NCI breast cancer family registry study

  2006cited by this paper
• HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

  2006cited by this paper
• Concordance among gene-expression-based predictors for breast cancer.

  2006cited by this paper
• Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.

  2006cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Impact of a national external quality assessment scheme for breast pathology in the UK

  2006cited by this paper
• A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.

  2006cited by this paper
• Converting a breast cancer microarray signature into a high-throughput diagnostic test

  2006cited by this paper
• Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.

  2006cited by this paper
• Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

  2006cited by this paper
• Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials

  2005cited by this paper
• Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.

  2005cited by this paper
• Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

  2005cited by this paper
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  2005cited by this paper
• Free-Marginal Multirater Kappa (multirater K[free]): An Alternative to Fleiss' Fixed-Marginal Multirater Kappa.

  2005cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

  2004cited by this paper
• Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union—an inter-laboratory study

  2004cited by this paper
• Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

  2004cited by this paper
• A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

  2004cited by this paper
• The Use of TMA for Interlaboratory Validation of FISH Testing for Detection of HER2 Gene Amplification in Breast Cancer

  2004cited by this paper
• Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma

  2004cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• Ectopic pregnancy rates with day 3 versus day 5 embryo transfer: a retrospective analysis

  2003cited by this paper
• Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

  2002cited by this paper

• Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy.

  2026cites this paper
• Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.

  2025cites this paper
• Research progress on estrogen receptor-positive/progesterone receptor-negative breast cancer

  2025cites this paper
• B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer

  2025cites this paper
• Prognostic Value of Tumor Infiltrating Lymphocytes in Luminal B Breast Cancer Based on Multiphoton Microscopy

  2025cites this paper
• CAND1 mediates CUL7-dependent HER2 protein stability to drive breast cancer progression

  2025cites this paper
• Proteostasis Disruption by Proteasome Inhibitor MG132 and Propolin G Induces ER Stress‐ and Autophagy‐Mediated Apoptosis in Breast Cancer

  2025cites this paper
• Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2- breast cancer uncovers biomarkers of tumour response

  2025cites this paper
• Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer

  2025cites this paper
• A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer

  2025cites this paper
• PATHOLOGIC AND MOLECULAR SUBTYPES CHARACTERISTICS OF OUR BREAST CANCER PATIENTS IN KOSOVO

  2025cites this paper
• Optimizing transcriptome-based synthetic lethality predictions to improve precision oncology in early-stage breast cancer: BC-SELECT

  2025cites this paper
• Contrast-enhanced mammography for tumor size assessment and detection of multifocal and multicentric disease in breast cancer subtypes

  2025cites this paper
• Machine learning-based prediction of luminal breast cancer subtypes using polarised light microscopy

  2025cites this paper
• Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study

  2024cites this paper
• Deep Learning Predicts Subtype Heterogeneity and Outcomes in Luminal A Breast Cancer Using Routinely Stained Whole-Slide Images

  2024cites this paper
• Characterization of HER2‐low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study

  2024cites this paper
• Epigenetic Therapies in Triple-Negative Breast Cancer: Concepts, Visions, and Challenges

  2024cites this paper
• Unraveling the future: Innovative design strategies and emerging challenges in HER2-targeted tyrosine kinase inhibitors for cancer therapy.

  2024cites this paper
• The Evolving Role of Genomic Testing in Early Breast Cancer: Implications for Diagnosis, Prognosis, and Therapy

  2024cites this paper
• Machine Learning–Supported Diagnosis of Small Blue Round Cell Sarcomas Using Targeted RNA Sequencing

  2024cites this paper
• NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence

  2024cites this paper
• Radiology–pathology correlation of hormonal subtypes of breast cancer based on mammography, ultrasound, and PET imaging

  2024cites this paper
• All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells

  2024cites this paper
• Respuesta tumoral a la quimioterapia neoadyuvante en subtipos moleculares de cáncer de mama en Medellín, Colombia. Estudio de cohorte retrospectivo

  2023cites this paper
• NCAPH Drives Breast Cancer Progression and Identifies a Gene Signature that Predicts Luminal A Tumor Recurrence

  2023cites this paper
• Inhibitory Effort of MLN2238 on Basal-Like Breast Cancer: An Investigation Based on the Gene Set Enrichment Analysis.

  2023cites this paper
• Implications of tumour heterogeneity on cancer evolution and therapy resistance: lessons from breast cancer

  2023cites this paper
• Crowding phenomenon in breast cancer as a prognostic factor

  2023cites this paper
• Hounsfield Units Predict Survival of Patients With Estrogen Receptor-Positive and Human Epithelial Growth Factor Receptor 2-Negative Breast Cancer.

  2023cites this paper
• Advancing Breast Cancer Heterogeneity Analysis: Insights from Genomics, Transcriptomics and Proteomics at Bulk and Single-Cell Levels

  2023cites this paper
• Molecular Subtypes and Ki-67 index in Breast Carcinoma with Special Emphasis on Triple Negative Breast Cancer. A 3-year Study in a Tertiary Care Center

  2023cites this paper
• Design, analysis, and interpretation of treatment response heterogeneity in personalized nutrition and obesity treatment research

  2023cites this paper
• Identification of long non-coding RNAs and RNA binding proteins in breast cancer subtypes

  2022cites this paper
• Imaging features of breast cancer molecular subtypes: An Updated Review of the Literature

  2022influential citation
• Pathogenesis of Triple-Negative Breast Cancer.

  2022cites this paper
• Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer

  2022cites this paper
• Application of informatics in cancer research and clinical practice: Opportunities and challenges

  2022cites this paper
• Antitumor Potential of Sericite Treatment Mediated by Cell Cycle Arrest in Triple-Negative MDA-MB231 Breast Cancer Cells

  2022cites this paper
• Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients

  2022cites this paper
• Breast Cancer-Delivered Exosomal miRNA as Liquid Biopsy Biomarkers for Metastasis Prediction: A Focus on Translational Research with Clinical Applicability

  2022cites this paper
• Multiregional Radiomic Signatures Based on Functional Parametric Maps from DCE-MRI for Preoperative Identification of Estrogen Receptor and Progesterone Receptor Status in Breast Cancer

  2022cites this paper
• Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer

  2022cites this paper
• Construction of a lncRNA-mediated ceRNA network and a genomic-clinicopathologic nomogram to predict survival for breast cancer patients

  2022cites this paper
• Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation

  2022cites this paper
• Identifying the Best Ki-67 Cut-Off for Determining Luminal Breast Cancer Subtypes Using Immunohistochemical Analysis and PAM50 Genomic Classification

  2022cites this paper
• Breast Cancer Disease Burden in Albania

  2022cites this paper
• Decision Theory versus Conventional Statistics for Personalized Therapy of Breast Cancer

  2022cites this paper
• Gene expression signatures in early Breast Cancer: better together with clinicopathological features.

  2022cites this paper
• Subclonal heterogeneity and evolution in breast cancer

  2021cites this paper
• Adjuvant chemotherapy could not bring survival bene�t to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

  2021cites this paper
• Magnetic Resonance Imaging Phenotypes of Breast Cancer Molecular Subtypes: A Systematic Review.

  2021cites this paper
• HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness

  2021cites this paper
• Planning Adjuvant Treatment

  2021cites this paper
• Dissecting the biological heterogeneity of HER2-positive breast cancer

  2021cites this paper
• CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis Degradation

  2021cites this paper
• Validation of the Skåne University Hospital nomogram for the preoperative prediction of a disease-free axilla in patients with breast cancer

  2021cites this paper
• Luminal A breast cancer resistance mechanisms and emerging treatments

  2021cites this paper
• Benefits of Neoadjuvant Chemotherapy for Luminal Breast Cancer with Respect to Tumor Response

  2021cites this paper
• Impact of molecular subtype and race on HR+, HER2− breast cancer survival

  2021cites this paper
• Validation of the Ska˚ne University Hospital nomogram for the preoperative prediction of a disease-free axilla in patients with breast cancer

  2021cites this paper
• Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy

  2021cites this paper
• Role of immune regulatory cells in breast cancer: Foe or friend?

  2021cites this paper
• Comparative survival analysis of multiparametric tests—when molecular tests disagree—A TEAM Pathology study

  2021cites this paper
• Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

  2021cites this paper
• A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape

  2021cites this paper
• Decision theory for precision therapy of breast cancer

  2021influential citation
• Trefoil factor 1 (TFF1) is a potential prognostic biomarker with functional significance in breast cancers.

  2020cites this paper
• KDM2B Silencing Elicits a Paracrine Mechanism Which Destabilizes SLUG, Promoting Differentiation of Basal-Like Breast Cancer Cells

  2020cites this paper
• Spatial transcriptomics inferred from pathology whole-slide images links tumor heterogeneity to survival in breast and lung cancer

  2020cites this paper
• Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review

  2020cites this paper
• An in-silico method leads to recognition of hub genes and crucial pathways in survival of patients with breast cancer

  2020cites this paper
• Notch activation in the mouse mammary luminal lineage leads to ductal hyperplasia and altered partitioning of luminal cell subtypes.

  2020cites this paper
• Heterogeneous Domain Adaptation for IHC Classification of Breast Cancer Subtypes

  2020cites this paper
• Overestimation of Late Distant Recurrences in High-Risk Patients With ER-Positive Breast Cancer: Validity and Accuracy of the CTS5 Risk Score in the TEAM and IDEAL Trials.

  2020cites this paper
• Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis

  2020cites this paper
• Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training

  2020cites this paper
• Investigating a Breast Cancer Gene Expression Data Using a Novel Clustering Approach

  2019cites this paper
• Identification of hub genes and important pathways in determination of breast cancer survival using bioinformatics approaches

  2019cites this paper
• Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0–1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database

  2019cites this paper
• Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.

  2019cites this paper
• Deciphering HER2 Breast Cancer Disease: Biological and Clinical Implications

  2019cites this paper
• SP 1 and STAT 3 Functionally Synergize to Induce the RhoU Small GTPase and a Subclass of Non-canonical WNT Responsive Genes Correlating with Poor Prognosis in Breast Cancer

  2019cites this paper
• The Need for Multi-Omics Biomarker Signatures in Precision Medicine

  2019cites this paper
• Clinical Utility of PET/CT in Breast Cancer Management and Targeted Therapy

  2019cites this paper
• Predictive biomarkers for drug response in bladder cancer

  2019cites this paper
• Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series

  2019cites this paper
• OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine

  2019cites this paper
• miRNAs and Long-term Breast Cancer Survival: Evidence from the WHEL Study

  2019cites this paper
• Should a Multigene Signature be Used in all Luminal Early Breast Cancers

  2019cites this paper
• Clinical target sequencing for precision medicine of breast cancer

  2019cites this paper
• Triple Negative Breast Cancer Profile, from Gene to microRNA, in Relation to Ethnicity

  2019cites this paper
• Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells

  2019cites this paper
• Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series

  2019cites this paper
• From latency to overt bone metastasis in breast cancer: potential for treatment and prevention

  2019cites this paper
• Research-based PAM50 signature and long-term breast cancer survival

  2019cites this paper
• Higher ER load is not associated with better outcome in stage 1–3 breast cancer: a descriptive overview of quantitative HR analysis in operable breast cancer

  2019cites this paper
• Molecular Carcinogenesis

  2019cites this paper
• The dysregulation of tRNAs and tRNA derivatives in cancer

  2018cites this paper
• The combined pN stage and breast cancer subtypes in breast cancer: a better discriminator of outcome can be used to refine the 8th AJCC staging manual

  2018cites this paper